Asia-Pacific’s medical devices industry saw a rise of 4.55% in deal activity during June 2022, when compared with the last 12-month average, led by Boston Scientific’s $230m acquisition of M.I.Tech, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 46 medical devices industry deals worth $755.9m were announced for the region in June 2022, against the 12-month average of 44 deals.

Of all the deal types, venture financing saw most activity in June 2022 with 39 transactions, representing an 84.8% share for the region.

In second place was M&A with six deals, followed by private equity deals with one transactions, respectively capturing a 13.04% and 2.2% share of the overall deal activity for the month.

In terms of value of deals, venture financing was the leading category in Asia-Pacific’s medical devices industry with $453.39m, while M&A and private equity deals totalled $234.5m and $68m, respectively.

Asia-Pacific medical devices industry deals in June 2022: Top deals

The top five medical devices deals accounted for 67.2% of the overall value during June 2022.

The combined value of the top five medical devices deals stood at $508m, against the overall value of $755.9m recorded for the month.

The top five medical devices industry deals of June 2022 tracked by GlobalData were:

1) Boston Scientific $230m acquisition deal for 64% stake in M.I.Tech

2) The $100m venture financing of Axbio by AstraZeneca Zhongjin Medical Industry Fund,Cambridge Capital Group,SDIC China Merchants Investment Management,Wuyuan Capital and Yunfeng Fund L.P

3) Creador Sdn and India Life Sciences Fund III $68m private equity deal with Accumax Lab Technology

4) The $60m venture financing of InSilico Medicine by B Capital Group,Bohai Harvest RST (Shanghai) Equity Investment Fund,Bold Capital Partners,Pavilion Capital,Qiming Venture Partners and Warburg Pincus

5) BioTrack Capital,CICC Fund Management,CR-CP Life Science Fund,Deguan Capital,Haoreng Capital,Pappas Capital,Sequoia Capital China,Shanghai Pan Lin Asset Management and Yonghua Capital $50m venture financing deal with NuProbe Global